Watch the EULAR presentation June 3–6 for updated patient numbers and response data. Positive incremental data could de-risk the asset modestly, but this is early Phase 1 — no pivotal catalyst.
Price Chart
Executive Summary
Cullinan Therapeutics announced that interim Phase 1 data for CLN-978 (CD19xCD3 T cell engager) in RA and SLE will be presented at EULAR (June 3–6, 2026). The abstract reports a favorable safety profile at initial doses, robust B cell depletion, and early signals of clinical activity. No specific efficacy rates, dosing, or financial guidance were disclosed; this is an interim data update with no catalyst for approval or pivotal readout.
Key Facts
- Abstract reports favorable safety profile at initial dose levels for CLN-978 in RA and SLE Phase 1 studies.
- Robust B cell depletion in peripheral blood and tissue observed, with early signals of promising clinical activity.
- Updated data including additional patients to be presented at EULAR Congress June 3–6, 2026, London.
- CLN-978 is a wholly owned, subcutaneously administered CD19xCD3 T cell engager targeting autoimmune diseases.
- No specific efficacy rates, response rates, or quantitative clinical outcomes disclosed in the press release.
Financial Impact
No financial data or guidance disclosed; clinical-stage, no approved product revenue.
Risk Factors
- Interim Phase 1 data may not be confirmed at EULAR or in later cohorts.
- Competition from approved B-cell targeting therapies (e.g., CAR-Ts, bispecifics in autoimmunity) is intense.
- No timeline provided for Phase 2 initiation or regulatory discussions.
- Cullinan has no approved products; clinical-stage biotech with binary pipeline risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3297050 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 24d ago | Press Release | $15.51 | awaiting T+60 | — | $14.55 (−6.19%) |
Sep 24, 2026 4w ago | 8-K | $15.44 | awaiting T+60 | — | $14.55 (−5.76%) |
Sep 24, 2026 4w ago | Press Release | $15.44 | awaiting T+60 | — | $14.55 (−5.76%) |
Sep 22, 2026 4w ago | Institutional Cluster | $21.67 | awaiting T+60 | — | $14.55 (−32.86%) |
Sep 14, 2026 6w ago | 8-K | $20.40 | awaiting T+60 | — | $14.55 (−28.68%) |
Aug 6, 2026 11w ago | 8-K | $17.95 | awaiting T+60 | — | $14.55 (−18.94%) |
Jun 11, 2026 19w ago | Institutional Cluster | $12.98 $21.69 | ▲ +67.10% | ▲ +63.28% | $14.55 (+12.10%) |
Jun 10, 2026 19w ago | Press Release | $12.05 $22.09 | ▲ +83.32% | ▲ +77.15% | $14.55 (+20.75%) |
Jun 8, 2026 20w ago | 8-K | $13.28 $22.33 | ▲ +68.15% | ▲ +64.64% | $14.55 (+9.56%) |
May 19, 2026 22w ago | Press Release | $14.18 $19.64 | ▲ +38.55% | ▲ +32.26% | $14.55 (+2.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers